Neuphoria Therapeutics Inc. NEUP
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.17M | -- | -- | -- | -13.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.17M | -- | -- | -- | -13.30K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.17M | -- | -- | -- | -13.30K |
| SG&A Expenses | 1.73M | 1.69M | 2.16M | 1.87M | 2.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.36M | 827.30K | 2.35M | 5.65M | 5.82M |
| Operating Income | -183.90K | -827.30K | -2.35M | -5.65M | -5.84M |
| Income Before Tax | -4.94M | -539.90K | 1.83M | -9.94M | -9.15M |
| Income Tax Expenses | -34.80K | -34.80K | -34.80K | -34.80K | -266.60K |
| Earnings from Continuing Operations | -4.90M | -505.10K | 1.86M | -9.91M | -8.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.90M | -505.10K | 1.86M | -9.91M | -8.88M |
| EBIT | -183.90K | -827.30K | -2.35M | -5.65M | -5.84M |
| EBITDA | -18.20K | -661.60K | -2.18M | -5.49M | -5.67M |
| EPS Basic | -0.91 | -0.09 | 0.41 | -4.41 | -4.67 |
| Normalized Basic EPS | -0.17 | -0.06 | 0.42 | -2.77 | -3.09 |
| EPS Diluted | -0.91 | -0.09 | -0.77 | -4.41 | -4.67 |
| Normalized Diluted EPS | -0.17 | -0.06 | 0.42 | -2.77 | -3.09 |
| Average Basic Shares Outstanding | 5.41M | 5.41M | 4.54M | 2.25M | 1.90M |
| Average Diluted Shares Outstanding | 5.41M | 5.41M | 4.54M | 2.25M | 1.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |